NLRP3 and inflammatory bowel disease: Notably, knockdown of VANGL2 or MARCH8 effectively boosts NLRP3 inflammasome activation in healthy PBMCs, and decreased VANGL2 results in overt NLRP3 inflammasome activation in the PBMCs of IBD patients.